Earnings call transcript: Solesence Q3 2025 sees stock plummet amid revenue drop

Solesence Inc. reported its Q3 2025 financial results, revealing a 14% year-over-year decline in revenue to $14.5 million, with a net loss of $1.1 million compared to a net income of $3 million in the same quarter last year. The company's stock suffered significantly, dropping 44.13% to $2.39 in premarket trading, reflecting investor concerns over its financial performance and future outlook.

Key Takeaways

• Revenue fell by 14% year-over-year, impacting overall financial performance.
• The stock price dropped over 44% in premarket trading.
• Solesence aims for a 30% margin floor by 2026 and anticipates growth above industry rates.

Company Performance

Solesence's Q3 2025 results showed a substantial decline in financial performance, with revenue decreasing by 14% to $14.5 million. This downturn was attributed to conservative customer inventory strategies and a general slowdown in the beauty industry, despite the growth in SPF-infused beauty segments. The company's gross profit also fell to $3.4 million from $6.1 million a year ago, resulting in a net loss of $1.1 million.

Financial Highlights

• Revenue: $14.5 million, down 14% year-over-year.
• Gross Margin: 23%, down from 36% last year.
• Net Loss: $1.1 million, compared to a net income of $3 million in Q3 2024.
• Adjusted EBITDA: Loss of $435,000, compared to a $3.6 million profit in the previous year.

Market Reaction

Following the earnings announcement, Solesence's stock price plummeted by 44.13% in premarket trading, settling at $2.39. This sharp decline reflects investor concerns over the company's decreased revenue and profitability, compounded by the broader market's cautious stance on the beauty industry. The stock's performance is particularly concerning given its 52-week low of $1.34, indicating heightened volatility and investor anxiety.

Outlook & Guidance

Looking ahead, Solesence projects full-year revenue of approximately $64 million, which marks an increase of $12 million from the previous year. The company is targeting a 30% margin floor by 2026 and expects to grow at a rate exceeding industry averages. Solesence plans to reinforce its position in the mineral-based SPF segment, which is anticipated to be one of the fastest-growing areas in the beauty industry over the next five years.

Executive Commentary

CEO Kevin Cureton emphasized the company's strategic focus, stating, "The future of sun care is the future of beauty." He expressed confidence in Solesence's ability to outperform industry growth rates, highlighting the company's technological leadership and manufacturing expertise as key competitive advantages. Cureton also addressed operational improvements, noting a 25% reduction in average labor costs per unit and increased equipment effectiveness.

Risks and Challenges

• Industry slowdown: The beauty market's general deceleration could continue to pressure revenue.
• Operational inefficiencies: Despite improvements, any lingering inefficiencies could impact margins.
• Competitive pressures: Maintaining technological leadership in a competitive field remains crucial.
• Macroeconomic factors: Broader economic conditions could affect consumer spending in beauty products.

Q&A

During the earnings call, analysts raised concerns about operational inefficiencies and revenue challenges linked to conservative customer inventory strategies. The company reassured investors of its commitment to improving margins and operational excellence, aiming to leverage its unique expertise in mineral-based SPF technology to drive future growth.

Full transcript - Solesence Inc (SLSN) Q3 2025:

Conference Operator: Good day, and thank you for standing by. Welcome to the Solesence Third Quarter 2025 conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To participate, you will need to press star 1-1 on your telephone. You will then hear a message advising your hand is raised. To withdraw your question, simply press star 1-1 again. We ask that you please keep your questions to one and re-queue if needed. Please note this conference is being recorded. During this call, management will make statements that include forward-looking statements within the meaning of the federal securities laws which are pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995.

This conference call may contain statements to reflect the company's current beliefs, and a number of important factors could cause actual results for future periods to differ materially from those stated on this call. These important factors include, without limitation, a decision of the customer to cancel purchase order or supplies, agreement demand for and acceptance of the company's personal care, ingredients, advanced materials and formulated products, changes in development and distribution relationships, the impact of competitive products and technology, possible disruption in commercial activities occasioned by public health issues, terrorist activity and armed conflict, and other risks indicated in the company's filings with the Securities and Exchange Commission. Except as required by federal securities laws, the company undertakes no obligation to update or revise these forward-looking statements to reflect new events, uncertainties, and other contingencies. I now hand the conference over to Kevin Cureton, President and Chief Executive Officer.

Please go ahead, sir.

Kevin Cureton, President and Chief Executive Officer, Solesence: Thank you, Operator. Thank you to all of our investors, teammates, and friends joining us today. We have a lot to cover, so we appreciate your time, patience, and attention. Today is a meaningful moment in the history of Solesence. This is my first opportunity to speak with you since stepping into the role of President and Chief Executive Officer. I am truly honored to take on this responsibility and energized by the incredible talent of our team and the strong opportunities ahead to continue growing profitably with our brand partners. It is also a significant moment for another reason. Today marks Jess's final earnings call as a member of the Solesence leadership team. Many of you know that Jess and I began this journey together in 2012 when he brought me in to help chart a new path forward.

The conversations we had during that interview process about transforming the business from a materials company into a product-focused organization became the foundation of what Solesence is today. Jess has been an exceptional partner to me and to all of us, working tirelessly to ensure we had the financial strength to grow, innovate, and establish ourselves as a leader in beauty innovation. With that, I'd like to turn it over to Jess for a few remarks. Jess?

Jess, Outgoing Executive (Last Name Not Specified), Solesence: Thanks, Kevin. Since this will be my final earnings call, I'd like to briefly touch on my time at Solesence and why now is the right time for Kevin to lead the company going forward. Over the past decade, Solesence pioneered the skin health and mineral-based beauty industry, establishing more than 90 globally issued patents across four technology platforms. By collaborating with our brand partners, the use of mineral-based active ingredients in beauty products has become more widespread. Now, we're seeing more and more brands infuse their products with SPF technology. We've grown at a CAGR of greater than 7x as compared to our addressable market in the skincare, color cosmetics, and sun care cosmetics areas and have won eight awards for product and technology innovation so far and are sure to win more. Now, we're the industry leader in this space.

As I pass the torch to Kevin, we believe we can expand on this position for several reasons. First, the complexity and difficult logistics that go into creating these types of products means that our industry has substantial barriers to entry that limit the number of potential competitors. Second, we possess a unique mix of expertise, best-in-class technology, and manufacturing capabilities that very few can match. Third, Solesence will maintain the same relentless commitment to scientific excellence and innovation that has always driven us. As I've reflected on my time here, I couldn't be more gratified by what we've accomplished. The transformation of Solesence is a testament to the hard work and dedication of our team, and I'm grateful for having the opportunity to work alongside so many talented individuals. It has been no less than a privilege.

This includes Kevin, with whom I've worked closely for over a decade. With his extensive industry experience, deep expertise, and vision, I'm confident that he is the right person to lead Solesence into this next exciting era of growth. I'll now pass the call to Kevin, who will provide a summary of the quarter as well as the vision and outlook for the company. Kevin?

Kevin Cureton, President and Chief Executive Officer, Solesence: Thank you, Jess, for your partnership. Again, congratulations. Turning now to our work today. I've been honored to be in leadership positions with Solesence for over a decade, including leading the founding and development of our core consumer beauty, health, and wellness business, which has grown into the company we are today. While that journey and the accomplishments Jess covered have all been important achievements, and we should feel rewarded, our entire organization knows we have much work ahead of us, as evidenced by our third quarter results. The third quarter of 2025 represented the first quarter in almost two years where we did not have a year-over-year revenue increase. Admittedly, Q3 2024 was a record quarter for our company in both revenue and profitability and represented the level of profitability and performance we expect, so the comparison was going to be difficult.

However, we remain confident in our ability both on a near-term and longer-term basis to continue to grow at a multiple of the industry's growth rate and remain highly profitable while doing so. Our confidence is reinforced by the growth plans of our strategic brand partners. Without exception, each of them is expecting to outperform the market in the same manner as they have over the previous two years. Our products are important drivers for these companies' revenue, typically representing 30-60% of their business volume. So their success is our success. These brands are winning in the key retail segments where consumers want to buy beauty products, specifically at specialty beauty retailers and through TikTok and Amazon. Revenue growth, combined with best-in-class profitability, comes from the combination of the changes we've made in our leadership and our organization's structure.

We believe three factors have hindered our ability to generate profitable growth. These are, one, product design; two, labor efficiency; and three, inventory control. I'll now touch on each of these areas in greater detail and how we addressed them in our recent changes. First, product design is related to having exacting specifications, not just in terms of what the product is made from, but also how it will be manufactured and how it will perform. For the Solesence business, this is more complex because, unlike many other beauty products, the products produced by Solesence are considered over-the-counter drug products. They must meet product performance criteria similar to what is required of prescription drug products while ensuring that the product delivers a joyful experience such that the consumer will buy it again and again.

We must be able to make it consistently at a high volume at a cost that is 20% or less of the retail value. Our ability to deliver on these criteria gives us a sustainable competitive advantage, which protects our business position and is a critical factor to achieving profitability standards we expect. Every day, on millions of units annually, we meet this standard. However, when we have underperformed in this area, it was a significant factor in our results. During the end of Q2 and all of Q3, we reorganized the team responsible for ensuring product integrity, creating a newly unified group accountable for product design from the initiation of product concept all the way to product shipment. This unified group, the Innovation and Product Integrity Group, is a combination of the R&D and quality departments.

Through the unification of this group under one leader, we have already seen improvements in both clarity of product requirements and control to ensure that products are made right the first time. The new leader, Yana Dvorak, who is just appointed as Vice President of Innovation and Product Integrity, is also being recognized by the renowned Cosmetic Executive Women's Group, or CEW, as they are more commonly known, as a 2025 Innovator Honoree. This honor reflects not just our confidence in Yana's ability to help us drive more profitable growth, but also the industry's awareness of her exceptional capabilities. Moving on to the next area of improvement, labor efficiency. This issue has long impacted our direct profit performance. To be clear, this is not just direct labor, but also is impacted by our maintenance and engineering efforts that drive both uptime and throughput.

As some of you know, we began investments in this area almost two years ago. These investments have included automating our processes and implementing overall equipment effectiveness, or OEE, which is a key metric for managing our manufacturing processes. While these investments initially enabled a significant improvement in capacity, it was only during Q3 that we started to see the positive impact on labor efficiency. Those improvements enabled our company to reorganize its operating schedule, virtually eliminating overtime expenses while maintaining improved operating capacity and flexibility. These improvements were reflected in a reduction of the average labor cost per unit by close to 25% on a year-over-year basis and an increase in our OEE performance by 10 percentage points. We further strengthened this area by reorganizing the reporting structure, which was partly enabled by consolidating our three facilities down to two.

The consolidation alone will yield a mid-six-figure reduction in annual operating costs. We further expect that the labor efficiency savings will contribute to a similar high six-figure to low seven-figure reduction in direct labor expense on an annual basis as we move forward. Finally, and perhaps most impactful, is our inventory control. The change in scope and scale of our customer base has brought a change in the scope and scale of both the number of raw materials and components that we purchase and the number of products that we produce. To put it in perspective, just six years ago, we generated 80% of our revenue, $8 million, from 40 products built around a dozen raw materials. In fact, 60% of our revenue resulted from just five products built around three raw materials.

Fast forward to today, 80% of our revenue, approximately $50 million, is generated by over 300 products and well over 1,500 different raw materials and components. It's easy to see how this change, when not effectively managed, can negatively impact our ability to realize the full profit potential of our company. I'll now briefly describe how some of the initial changes that have been put in place will help drive profitable growth. The change we made in manufacturing leadership now allows the most senior leaders in operations to be focused on addressing our supply chain challenges. Some of the first work that has occurred here is to increase material surveillance and control, resulting in almost daily tracking of variances that could occur through materials handling, consumption of materials in batch making, or spillage and waste.

By increasing surveillance, we're now able to capture the significant issues that can contribute to negative income and put in more impactful corrective actions. There is still much more to be done, but I'm confident in the ability of our team, whose leadership is now comprised of people with direct experience in the beauty and personal care industry. They come from organizations that are some of the largest and best operated in the business. I'll now turn the call over to Laura, who will provide a recap of our financial performance. Laura.

Jess, Outgoing Executive (Last Name Not Specified), Solesence: Thank you, Kevin. Good morning, everyone. I'm pleased to be joining you on today's call. Revenue for the third quarter was $14.5 million, a decrease of 14% year-over-year, amidst a general softening in the industry reflecting the shift in consumer behaviors. As Kevin mentioned earlier, last year's third quarter was a record quarter, creating a challenging comparable as our customers adjusted their inventory levels as compared to the third quarter of 2024. In the third quarter, our shift in open orders, which represent the total value of customer orders that we've either already shipped or are still awaiting fulfillment in 2025, is currently $64 million, compared to $34 million in the third quarter of last year and $60 million in the second quarter of 2025. Gross profit in the third quarter was $3.4 million compared to $6.1 million in the third quarter of 2024.

Gross margin was 23% compared to 36% for the same period last year. The decrease was related to manufacturing operating inefficiencies and facilities improvements. Operating expenses in the third quarter totaled $4.2 million compared to $2.9 million in the third quarter of 2024. The increase is due to increased employee-related costs, legal costs, allowance for credit loss, severance costs, and costs related to our uplisting to NASDAQ in 2025. During the third quarter, other income included an adjusted payment of $1.2 million relating to funds received from the U.S. Department of the Treasury under the Employee Retention Credit Program, along with approximately $300,000 in interest received related to the delayed payment. The ERC is a refundable payroll tax credit made available under the CARES Act and subsequent legislation. Interest income included interest paid relating to this amount of about $200,000 in the third quarter 2025.

The ERC payments and related interest did not apply to 2024. Solesence reported a net loss of $1.1 million compared to net income of $3 million in the third quarter of 2024. Adjusted EBITDA for the quarter was a loss of $435,000 compared to adjusted EBITDA of $3.6 million for the third quarter of last year. As Kevin noted, we made significant improvements to our business operations that will enable us to grow and deliver the highest quality products to our brand partners more efficiently and from a greater cost position. That concludes our opening remarks. Operator, you may open the call for questions.

Conference Operator: Thank you. As a reminder, to ask a question, simply press star 11 to get in the queue and wait for your name to be announced. To withdraw your question, press star 11 again. One moment for our first question. It comes from the line of Wayne Rowan. Please go ahead.

Wayne Rowan, Investor/Analyst: Congratulations, Jess. I hope your retirement goes well. I probably won't butt into you at Wrigley Field. But good luck to you.

Jess, Outgoing Executive (Last Name Not Specified), Solesence: No, you won't butt into me at Wrigley Field.

Wayne Rowan, Investor/Analyst: I'm very disappointed. This was supposed to be a better year. Are we making the same mistakes over and over again? Where do we get some optimism for the sales part? It bothers me a lot. What's the matter with that? The mistakes we made are not very comforting. I'd like your response, Kevin.

Kevin Cureton, President and Chief Executive Officer, Solesence: Good morning, Wayne. You might bump into me at Wrigley Field, by the way. Thank you for your questions. We do take all of these very seriously. Let's start with the first question, which was, are we making some of the same mistakes over and over? I can tell you, Wayne, that there are some areas that we have had a longer time to repair, which is why we made some of the changes that we've made to the organization over the last quarter. Specifically around inventory management, that is an area that has taken us more time than we would like to repair. With the changes that we've made, we're confident that we're on the right path to fixing that issue. Your other question was related to the revenue and what's going on there.

I think first, let's make sure we're clear, and we didn't talk about it in our prepared remarks, but on a full-year basis, we're up $10 million over the prior year. The trend for growth is strong. One of the things that has changed and is really related in part to consumer sentiment and our brand partners' desire to be conservative relative to their inventory levels is that they're not giving us the same lead time that they have in the past, and they're not stocking inventories at the same level that they had last year. That had a material impact on a year-over-year basis between what we saw in 2024 in terms of revenue and what we saw in 2025. I rest assured again that we have and continue to expect to grow at the top line. That is something that we're confident in.

The final point is to make sure we're clear that, yes, we are taking the profit growth very seriously. It is an important part of the planning that we've done and the adjustments that we've made in terms of structure and the changes that we've made in terms of some of the other processes that we mentioned during our prepared remarks.

Wayne Rowan, Investor/Analyst: Thank you. How come you waited so long to put out the third quarter? Because normally you do it the first week.

Kevin Cureton, President and Chief Executive Officer, Solesence: Yep. Another good question, Wayne. You've got a new leadership team that wanted to make sure we did it right the first time. That confused me.

Wayne Rowan, Investor/Analyst: There you go. That's fine.

Kevin Cureton, President and Chief Executive Officer, Solesence: I'm sorry.

Wayne Rowan, Investor/Analyst: I said, "There you go. That's a good idea. Thank you.

Kevin Cureton, President and Chief Executive Officer, Solesence: That's it. That was the reason.

Wayne Rowan, Investor/Analyst: Thank you. Do you look for do we have possibilities of greater sales reports for the fourth quarter this year?

Kevin Cureton, President and Chief Executive Officer, Solesence: Our expectation on a full-year basis is that we will see an improvement over the prior year. Yes, I think that in total, you'll see a positive revenue versus 2024. We're staying on that trend, Wayne. Yes.

Wayne Rowan, Investor/Analyst: Thank you.

Conference Operator: Thank you. Our next question comes from the line of Ronald Richards. Please proceed.

Ronald Richards, Investor/Analyst: Can you hear me?

Conference Operator: Yes, sir. We can hear you. Please proceed.

Kevin Cureton, President and Chief Executive Officer, Solesence: Hi, Ron.

Ron, Investor/Analyst: Hi. I've got a few questions, but I guess I'll start off with a really simple one. It was a really simple mistake that led to your big lawsuit a couple of years ago in a contract where there was one little sentence that somebody missed. Then this last quarter or two quarters ago, you had this $2 million error because of a screw-up on a new order. And this quarter, it's really, really simple. You might think it isn't meaningful, but the announcement for this conference call referred to Central Daylight Time and Eastern Daylight Time. All these things have a common point to them. Just the simple things, the details are overlooked. Is this going to improve, or are we going to continue having a series of simple mistakes that cause the problems we're having?

Kevin Cureton, President and Chief Executive Officer, Solesence: Thanks, Ron, for the question. Your first statement related to the lawsuit, I'm presuming you're referencing the BASF lawsuit. We'll agree to disagree on that. That wasn't really driven by contractual mistake or error. In fact, it was a decision—let's just put it this way—the simplest way for us to put it is just commercial points of difference. We did settle that in an amicable way with BASF. That has been an important part of, quite honestly, our ability to continue to scale the Solesence business. On the other two points, well taken. We certainly know that the details matter. It's an important part of our business. It's one of the things that we mentioned in our prepared remarks around product design and making sure that we have the exacting specifications clearly understood and stated. Thank you for that comment.

We are taking those things to heart, and it is an important part of what we're doing to improve the profit performance of the company.

Conference Operator: Our next question comes from the line of Stefano Bolis with—please proceed.

Stefano Bolis, Investor/Analyst: Hello. Good morning. Congratulations, Kevin, for your new role. Thanks to Jess for having sailed the vessel during all these years up to this point. Welcome to Laura.

Kevin Cureton, President and Chief Executive Officer, Solesence: Thank you, Savena.

Stefano Bolis, Investor/Analyst: Okay. Question is, the gross margin for this quarter, is this the fact that it's not around or slightly above the 30%? Is this because of this reorganization work that you mentioned initially, or was there something else?

Kevin Cureton, President and Chief Executive Officer, Solesence: Yeah. Your question related to gross margin is, just to be clear, Stefano, and hopefully you can respond to this. You're asking the cause of the lower gross margin. Is that what you're referring to?

Stefano Bolis, Investor/Analyst: Yeah. Yeah.

Kevin Cureton, President and Chief Executive Officer, Solesence: Okay. Yes. Yes. In part, the lower gross margins were related to the expenses with the consolidation that were not able to be capitalized. They were also related to the transition that we mentioned. We have good performance on a year-over-year basis at the direct labor level, where we actually decreased direct labor pretty significantly on a per-unit basis and in total. As that transition was occurring to the newer structures, we still had higher indirect expenses that we are addressing as we go forward. That was one of the big drags on the indirect, or excuse me, on the gross margin. I think Laura had mentioned some of the benefits of the changes that we are making. Laura, would you want to comment at all on those?

Laura, Financial Executive, Solesence: Obviously in the short time I have been with the company, we have taken seriously the indirect costs. I feel very confident that we are making the changes and having the discussions that are necessary to improve our overall indirect costs. I expect to see that improvement within the next few quarters and actually sooner than that.

Kevin Cureton, President and Chief Executive Officer, Solesence: Thank you.

Conference Operator: Our next question comes from the line of Tony Ruben. Please proceed.

Kevin Cureton, President and Chief Executive Officer, Solesence: Hi. Good morning. This is a couple of questions. Following up on the first gentleman's question who asked about your sales and margin forecasting, you just said sales would be up in 2025. They're, through the first three quarters, already up $10 million. As we're basically halfway through Q4, can you shed any light on what sales for the fourth quarter will look like and what margins will look like, as well as give us an outlook in some general sense as to 2026? Good morning, Tony. Yes, you're correct. The sales are up $10 million on a nine-month basis. As Laura indicated on a shift-in open, and you remember that metric that we've been using, we're projecting around $64 million for the year, essentially, which would put us up roughly $12 million on a full-year basis versus the prior year.

We are working through the changes that we mentioned. We are very confident in improving the direct margin levels on a continuing basis. That work is well in hand and is yielding the results that we expected. The indirect margins, or excuse me, indirect costs, I should say, that are contributing to the gross profit level are going to be, as Laura mentioned, work over the next couple of quarters to improve that. As we improve that over the next couple of quarters, we expect the margins to normalize back to levels that we have seen, say, a year ago this quarter. We do anticipate doing that as we go through the next couple of quarters or so.

In terms of a projection on 2026, because of the uncertainty that we're seeing from the marketplace and consumer sentiment, we're going to refrain from giving too much guidance there, except to say two things. One, we know that in general, most consumer markets are slowing down, and beauty is no exception to that. It is slowing. However, we're still confident that our growth rate will be a multiple of the industry's growth rate. We'll refrain from saying too much more than that at this point. Over the next coming weeks, we do plan on presenting our first investor presentation, Tony. That will give more guidance in terms of our expectations, not just for 2026, but for the next few years beyond that as well.

Conference Operator: Our next question comes from Stefano Bolis. Please proceed.

Ronald Richards, Investor/Analyst: Yeah.

Stefano Bolis, Investor/Analyst: Sorry. A follow-up on the indirect cost. Just for future modeling, the run rate of the SG&A expenses, is it going to stay on this $3 million that we have seen in the last two quarters, or is this due to those one-off impacts that you mentioned, the uplisting and some credit losses, allowances, and so on?

Kevin Cureton, President and Chief Executive Officer, Solesence: Yeah. Could you repeat your question? We had a hard time hearing you at the beginning of your question.

Stefano Bolis, Investor/Analyst: Okay. The question is on the expected run rate of the SG&A expenses. That, I mean, from historical levels were at $2 million or below $2 million, and last quarter and this quarter, they are $3 million. Is this the new level, or there was a lot of components that are one-off?

Kevin Cureton, President and Chief Executive Officer, Solesence: Yeah. I would say for planning purposes, we're operating in that zone on a going-forward basis. I think that some additions to our leadership team are part of that, obviously, to help strengthen the organization and to improve our overall performance. We've obviously added Laura. We've also added a VP of HR. There's been some other support functions added in there as well. Generally, for the business as we're operating right now, we have a little higher legal fees than we've had historically. It is something that, given the nature of our business, we've got to at least plan for that over the next few quarters. There was also, Stefano, though, a significant hit for me. There was a $400,000. You have to take the expenses for severance at one time. That will not repeat going forward.

Right there, that's 15% of that total is not coming back. We also think that, generally speaking, we are going to have all of our doubtful accounts run through SG&A, not COGS. We believe we are going to have better experience in that going forward. That is going to mitigate some of the investments we are making on the other side to do that.

Conference Operator: Our next question comes from Tony Ruben. Please proceed.

Ronald Richards, Investor/Analyst: Yeah. Hello. Just wanted to follow up to your response to Kevin on margins. You indicated that you thought margins would get back to a level of a year ago. What is your expected or target 2026 margins? Given all the spends on capital efficiency measures, etc., etc., you still, I think no matter what number you say, are going to be short of your COVID-era margins where you were in that 40% range. Is that something that we will ever see again? As you mentioned, the company is, in your words, or to paraphrase, a leader in making these complex formulations that the market does want. Just kind of as a side follow-up, I guess I'm trying to cram a lot in here. You mentioned that you will grow at multiples of the industry, but that the industry is softening.

If you could clarify what exactly that means, because it's pretty difficult to parse that.

Kevin Cureton, President and Chief Executive Officer, Solesence: Yeah. I'm going to—thank you. Thank you, Tony. There were three very important questions there. We'll try and make sure we answer them all. I will say to the team that's managing this call, if we fall short, please let Tony re-queue so I can answer that third question. Let's start at the top on the margins. Our guidance at this point, Tony, we're going to refrain from giving too much guidance on 2026. We will be prepared to provide further guidance soon. We absolutely expect that our goal is 30% is really the floor for our guidance, not the ceiling. That's all we're going to be prepared to say today, at least on 2026. In terms of COVID-era margins, one of the things we talked a lot about as a leadership team was what is the margins that we anticipate achieving.

We view ourselves as a technology leader, as you mentioned. Quite honestly, the investments that we make in IP that have translated into our growth reinforce that. All of the different patents that are unique in terms of a company our size and operating in such a focused market as we do in terms of being able to represent us as a technology company. We expect to achieve margins in that 40% plus range that is an objective for our business. We know that that will not be something we can do overnight. At the very top of that list, we are doing a much better job at driving direct margin performance. Ultimately, with some improvements at the indirect level, we will be able to improve overall growth margins as well. I think the third question I am looking at, Laura, do not remember.

Laura, Financial Executive, Solesence: I don't remember the third question.

Kevin Cureton, President and Chief Executive Officer, Solesence: Tony, if you can re-.

Laura, Financial Executive, Solesence: Repeat that for us?

Kevin Cureton, President and Chief Executive Officer, Solesence: Yeah. Re-queue and repeat. That would be helpful. Thank you.

Conference Operator: Tony, your line is open.

Ronald Richards, Investor/Analyst: I think you gave the flavor of what I was asking. I would hope for more specificity. I would hope 30% would be considered a disaster, not even a floor with respect to that. I do applaud the company having an investor presentation, presumably to get some institutional shareholdings and to articulate the story. As I'm sure you're aware, the stock has plunged in recent weeks, which, as I'm sure everybody on this call and the management team especially is not happy with. The ability to provide more clarity going forward certainly would be appreciated. Frankly, the company has excelled at R&D, has been good to great at sales, but has continually failed on operations. Any measures that can really fix those issues and could instill confidence in the community, I'm sure would be rewarded in spades and to the benefit of all.

Good luck and Godspeed. Thank you.

Kevin Cureton, President and Chief Executive Officer, Solesence: Thank you, Tony. I think his last question that we all forgot was about the multiple of the market relative to how our growth was going to be. Yes. Yes. Thank you. I'm glad somebody's paying attention here.

Ronald Richards, Investor/Analyst: Jess, you can always have a job in helping us answer those questions.

Kevin Cureton, President and Chief Executive Officer, Solesence: Thank you, Tony, for your comments. I do think that we will take that praise well, that we've been excellent at R&D and good to great on the sales and marketing side of the organization. We also accept the criticism that the company needs to improve in operations. That's really a reflection of a lot of the changes that we've made and announced. It's also reflected in the type of recruiting that we've done over the last year and a half in terms of bringing in really excellent people from top organizations that have been in the beauty and personal care industry and understand what it takes to translate the products that we design into finished goods that are meeting or exceeding our profit expectations. In terms of the going forward and what's happening in the industry, generally, the industry is slowing down.

I will say that one of the good parts of our focus is that the SPF-infused beauty areas where we operate are continuing to be strong. They are growing faster generally than the industry. Our benefit has been over the past few years is that along with the growth of SPF-infused beauty, consumers' preference in that space has tended and trended toward mineral-based SPF-infused beauty. You combine that consumer preference with the growth in the industry, that means that generally, mineral-based SPF-infused beauty is gaining share against other types of approaches to providing SPF.

That said, then further, as you have already mentioned, Tony, our leadership around technology and enabling that technology, quite honestly, enables us to have preferential aesthetics in terms of transparency on skin, the lightness of the textures, the fullness of coverage when required, or transparency and the skin-like appearance that our products can deliver, all are preferences. That has helped us through having some great brand partners to really be able to grow at a multiple of the industry. We continue to expect through our investments in those brand partners to sustain that growth rate.

Conference Operator: Our next question is from Ronald Richards. Please proceed.

Jess, Outgoing Executive (Last Name Not Specified), Solesence: I wanted to follow up with my first question. I didn't really understand this ERC payment. Was that in this Q3, or was that in last year's Q3? I thought you said it was in this year's Q3. Without that payment, would the financials have been $1.3 million worse?

Laura, Financial Executive, Solesence: Hi, Ron. Thank you for your question. The ERC payment was in this quarter, third quarter of 2025. You are correct.

Jess, Outgoing Executive (Last Name Not Specified), Solesence: Man, that doesn't sound good for total bottom line here.

Laura, Financial Executive, Solesence: It would have impacted, obviously, our bottom line for the third quarter.

Conference Operator: Ladies and gentlemen, this concludes our Q&A session. I will pass back to Kevin Cureton for concluding remarks.

Kevin Cureton, President and Chief Executive Officer, Solesence: Thank you, Carmen. Back in 2019, when the consumer products business was less than $2 million, that was the first time that our company used the phrase, "The future of sun care is the future of beauty." Looking forward, we believe that remains true. Consider that sun care is expected to be one of the fastest-growing segments in beauty over the next five years. Furthermore, we observe that the ongoing transition of daytime products to incorporate UV protection as a key benefit enabling longevity, health, and wellness. Because of these market dynamics, our technological and product leadership, and commitment to driving improvements in operations that will yield significantly improved profitability, we remain confident and committed to delivering best-in-class performance, not just to consumers, but also to our shareholders. In the coming weeks, we will release our first investor presentation.

This will help each of you further understand our confidence in our future and the returns that our business can deliver to our investors. Like longevity and health, our process to deliver these results is a journey. We appreciate all of you who will remain on this journey with us, as we believe, like the prior five years, the next five years will yield dynamic returns for all our investors. Thank you, and have a great day and happy holiday season to all of you.

Conference Operator: Ladies and gentlemen, this concludes our conference. Thank you for participating. You may now disconnect.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.